Company news

AbCellera Biologics Inc. news in 2021

AbCellera Biologics Inc.'s news releases, calls and decks from 2021, newest first.

View company

AbCellera Announces Changes to Its Board of Directors

December 6, 2021

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12

December 2, 2021

AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

December 1, 2021

AbCellera Reports Q3 2021 Business Results

November 8, 2021

AbCellera Announces Virtual Presentations at Investor Conferences in November

November 3, 2021

AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

October 13, 2021

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

September 21, 2021

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

September 20, 2021

Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

September 15, 2021

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

September 14, 2021

AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

September 12, 2021

AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

September 9, 2021

AbCellera Reports Q2 2021 Business Results

August 11, 2021

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines

August 3, 2021

Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer

August 2, 2021

AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021

July 21, 2021

AbCellera Appoints Neil Berkley as Chief Business Officer

July 12, 2021

AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada

June 21, 2021

AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares

June 9, 2021

CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results

May 12, 2021

AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

May 10, 2021

AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy

May 5, 2021

New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials

May 3, 2021

AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals

April 28, 2021

AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021

April 20, 2021

AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

April 13, 2021

AbCellera to Present Virtually at Upcoming Investor Conferences

April 11, 2021

Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19

April 4, 2021

AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration

March 31, 2021

AbCellera Reports Full Year 2020 Business Results

March 28, 2021

AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19

March 9, 2021

EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients

March 4, 2021

AbCellera to Present at the SVB Leerink Global Healthcare Conference

February 16, 2021

AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer

February 10, 2021

AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19

February 8, 2021

AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call

February 2, 2021

AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19

January 26, 2021

AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%

January 25, 2021

AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents

January 20, 2021

AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology

January 18, 2021

Calls in 2021

Decks in 2021